Werner Geldenhuys
Cited by
Cited by
Oxidative stress and Alzheimer’s disease: dietary polyphenols as potential therapeutic agents
AS Darvesh, RT Carroll, A Bishayee, WJ Geldenhuys, CJ Van der Schyf
Expert review of neurotherapeutics 10 (5), 729-745, 2010
Brain iron toxicity: differential responses of astrocytes, neurons, and endothelial cells
JA Gaasch, PR Lockman, WJ Geldenhuys, DD Allen, CJ Van der Schyf
Neurochemical research 32, 1196-1208, 2007
Pharmacology and structure‐activity relationships of bioactive polycyclic cage compounds: a focus on pentacycloundecane derivatives
WJ Geldenhuys, SF Malan, JR Bloomquist, AP Marchand, ...
Medicinal research reviews 25 (1), 21-48, 2005
Curcumin and neurodegenerative diseases: a perspective
AS Darvesh, RT Carroll, A Bishayee, NA Novotny, WJ Geldenhuys, ...
Expert opinion on investigational drugs 21 (8), 1123-1140, 2012
Optimizing the use of open-source software applications in drug discovery
WJ Geldenhuys, KE Gaasch, M Watson, DD Allen, CJ Van der Schyf
Drug discovery today 11 (3-4), 127-132, 2006
Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers
W Geldenhuys, T Mbimba, T Bui, K Harrison, V Sutariya
Journal of drug targeting 19 (9), 837-845, 2011
Role of serotonin in Alzheimer’s disease: a new therapeutic target?
WJ Geldenhuys, CJ Van der Schyf
CNS drugs 25 (9), 765-781, 2011
Molecular determinants of blood–brain barrier permeation
WJ Geldenhuys, AS Mohammad, CE Adkins, PR Lockman
Therapeutic delivery 6 (8), 961-971, 2015
Multifunctional drugs with different CNS targets for neuropsychiatric disorders
CJ Van der Schyf, WJ Geldenhuys, MBH Youdim
Journal of neurochemistry 99 (4), 1033-1048, 2006
Paclitaxel–hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model
RK Mittapalli, X Liu, CE Adkins, MI Nounou, KA Bohn, TB Terrell, ...
Molecular cancer therapeutics 12 (11), 2389-2399, 2013
In vivo brain microdialysis: advances in neuropsychopharmacology and drug discovery
AS Darvesh, RT Carroll, WJ Geldenhuys, GA Gudelsky, J Klein, ...
Expert opinion on drug discovery 6 (2), 109-127, 2011
The emergence of designed multiple ligands for neurodegenerative disorders
WJ Geldenhuys, MBH Youdim, RT Carroll, CJ Van der Schyf
Progress in neurobiology 94 (4), 347-359, 2011
Targeting the blood-brain barrier to prevent sepsis-associated cognitive impairment
DC Nwafor, AL Brichacek, AS Mohammad, J Griffith, BP Lucke-Wold, ...
Journal of central nervous system disease 11, 1179573519840652, 2019
Polycyclic cage structures as lipophilic scaffolds for neuroactive drugs
J Joubert, WJ Geldenhuys, CJ Van der Schyf, DW Oliver, HG Kruger, ...
ChemMedChem 7 (3), 375-384, 2012
Molecular insights into human monoamine oxidase B inhibition by the glitazone antidiabetes drugs
C Binda, M Aldeco, WJ Geldenhuys, M Tortorici, A Mattevi, ...
ACS medicinal chemistry letters 3 (1), 39-42, 2012
NGP1-01, a lipophilic polycyclic cage amine, is neuroprotective in focal ischemia
A Mdzinarishvili, WJ Geldenhuys, TJ Abbruscato, U Bickel, J Klein, ...
Neuroscience letters 383 (1-2), 49-53, 2005
Rationally designed multi-targeted agents against neurodegenerative diseases
W J Geldenhuys, C J Van der Schyf
Current medicinal chemistry 20 (13), 1662-1672, 2013
Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders
RT Carroll, D Bhatia, W Geldenhuys, R Bhatia, N Miladore, A Bishayee, ...
Journal of drug targeting 18 (9), 665-674, 2010
mitoNEET as a novel drug target for mitochondrial dysfunction
WJ Geldenhuys, TC Leeper, RT Carroll
Drug discovery today 19 (10), 1601-1606, 2014
Pharmacotherapy of Alzheimer’s disease: current and future trends
WJ Geldenhuys, AS Darvesh
Expert review of neurotherapeutics 15 (1), 3-5, 2015
The system can't perform the operation now. Try again later.
Articles 1–20